Field Medical筹集 3500万美元以推进消融系统开发-动脉网

Field Medical raises $35m to advance ablation system development

Medical Device Network 等信源发布 2025-07-02 08:08



可切换为仅中文







The FieldForce system provides a new method for creating transmural lesions in VT ablation. Credit: Field Medical / PRNewswire.

FieldForce系统为VT消融术中创建透壁病变提供了一种新方法。来源：Field Medical / PRNewswire。

Field Medical has closed a $35m series B financing round for advancing the development of the FieldForce pulsed field ablation platform.

Field Medical 已完成了一轮 3500 万美元的 B 轮融资，以推进 FieldForce 脉冲场消融平台的开发。

This round was co-led by BioStar Capital and Cue Growth, with contributions from current strategic investors.

本轮由BioStar Capital和Cue Growth共同领投，现有战略投资者亦有参与。

Go deeper with GlobalData

深入了解更多全球数据

Reports

报告

Balloon Sinuplasty Systems Market Size (Value, Volume, ASP) by Segm...

气球鼻窦成形术系统市场规模（价值、数量、平均售价）按细分市场...

Reports

报告

Innovation in Healthcare: Thermal Ablation Instruments

医疗创新：热消融仪器

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Find out more

了解更多

The funds will also facilitate the launch of the pivotal VERITAS trial and strengthen the company’s clinical and regulatory capabilities. It brings Field Medical’s total funding to $75m.

这笔资金还将有助于启动关键的VERITAS试验，并加强公司的临床和监管能力。这使得Field Medical的总融资达到7500万美元。

BioStar Capital founder and senior managing director Dr Louis Cannon said: “Field Medical’s transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency.

BioStar Capital 创始人兼高级董事总经理 Louis Cannon 博士表示：“Field Medical 的变革性技术正在做少数公司敢做的事情——以真正的创新和紧迫感应对心脏病学中最困难且未被充分解决的挑战之一。

“Their physician-led team brings the right insight, and their FieldForce platform brings the right tools.”

“他们的医生领导的团队带来了正确的见解，他们的FieldForce平台带来了合适的工具。”

In 2024, the FieldForce ablation system received

2024年，FieldForce消融系统获得

breakthrough device designation

突破性设备指定

and was selected for the US Food and Drug Administration (FDA) TAP Pilot programme for ventricular tachycardia (VT).

并入选美国食品和药物管理局（FDA）心室性心动过速（VT）TAP试点计划。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会作出反应还是提前预测？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

全球数据

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

The next-generation system has been designed for transmural lesion creation and provides a new approach to VT ablation.

下一代系统旨在创造透壁病变，并为室速消融提供了新的方法。

It remains an investigational device, limited to research use under US law.

它仍然是一种研究性设备，根据美国法律限制用于研究用途。

Field Medical founder and CEO Dr Steven Mickelsen said: “VT is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need.

Field Medical创始人兼首席执行官史蒂文·米克尔森博士表示：“室性心动过速是电生理学中渗透率最低的细分领域之一，但医生们仍然缺乏所需的工具。

“We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.”

“我们准备通过下一代疗法来解锁这一机会，该疗法以速度、精准和真正的临床进展为目标，朝着关键的准备阶段迈进，并重新定义高危患者室性心动过速护理的可能性。”

In conjunction with this growth funding, Field Medical has updated its board of directors.

与此增长资金的同时，Field Medical 更新了其董事会。

The board includes Dr Steven Mickelsen, the company’s founder and CEO; Mark Wisniewski, CFO of Enterra Medical; and Marlou Janssen, board member at Field Medical, Sonion, Acarix, EBAMed and Inspiration Healthcare.

董事会包括公司创始人兼首席执行官史蒂文·米克尔森博士、Enterra Medical的首席财务官马克·维尼耶夫斯基，以及Field Medical、Sonion、Acarix、EBAMed和Inspiration Healthcare的董事会成员马尔卢·扬森。

Additional members comprise surgeon and entrepreneur Alexei Mlodinow and Cue Growth founding partner Ben Cannon.

其他成员包括外科医生兼企业家阿列克谢·姆洛迪诺夫和Cue Growth的创始合伙人本·坎农。

注册获取我们的每日新闻汇总！

Give your business an edge with our leading industry insights.

利用我们领先的行业洞察，为您的业务提供优势。

Medical Device Network Excellence Awards - Have you nominated?

医疗器械网络卓越奖——您提名了吗？

Nominations are now open for the prestigious

提名现已开放，以角逐声望卓著的

Medical Device Network Excellence Awards

医疗器械网络卓越奖